Query: Characterization of insulin resistance and metabolic dysfunction in PCOS cell models: glucose transporter expression, insulin receptor substrate phosphorylation, mitochondrial biogenesis and respiration assays, reactive oxygen species generation, lipid droplet accumulation, and candidate biochemical endpoints for high-content screening

The characterization of insulin resistance and metabolic dysfunction in PCOS cell models requires a multiparametric approach that assesses several biochemical endpoints to recapitulate the complex in vivo milieu. First, evaluation of glucose transporter expression is fundamental. In PCOS models, the insulin-responsive transporter GLUT4 is of particular interest, as its translocation to the plasma membrane is impaired during insulin resistance. Techniques such as immunofluorescence, immunoblotting, and assays using fluorescent glucose analogues (e.g., 2-NBDG) provide quantitative measures of both basal and insulin-stimulated GLUT4 levels (yang2024experimentalcellmodels pages 8-9).

Equally important is the assessment of insulin receptor substrate (IRS) phosphorylation. IRS phosphorylation serves as an early readout of insulin signaling engagement, and defects here—such as reduced phosphorylation at specific serine or tyrosine residues—are indicative of disrupted insulin signal transduction. Western blot analysis and RT-PCR methods allow for detection of phosphorylation status changes in IRS isoforms (e.g., IRS-1), providing a molecular snapshot of insulin resistance (NCT02302326). Moreover, several studies have highlighted the significance of IRS1 Ser307 phosphorylation as an indicator of impaired insulin sensitivity, a change that is often mirrored in PCOS cell models (yang2024experimentalcellmodels pages 9-10).

Mitochondrial biogenesis and respiration assays are critical for linking energy metabolism with insulin sensitivity. In PCOS cells, impaired mitochondrial function contributes to overall metabolic dysfunction. Using approaches such as high-resolution respirometry and measurements of mitochondrial oxygen consumption and membrane potential, researchers can quantify defects in mitochondrial respiration. Additionally, the measurement of mitochondrial mass and biogenesis markers (e.g., PGC-1α levels) provides further context to the energy deficits observed in PCOS models (NCT02943291). These methods are complemented by assessments of oxidative phosphorylation capacity, which together yield an integrative view of mitochondrial performance (yang2024experimentalcellmodels pages 10-12).

Another important aspect is the generation of reactive oxygen species (ROS). Elevated ROS production is a hallmark of insulin resistance and contributes to oxidative stress, which in turn disrupts insulin signaling. ROS generation can be measured using fluorometric assays or specific dyes that allow real-time monitoring in living cells. Establishing a robust method for quantifying ROS levels in PCOS cell models aids in correlating oxidative stress with impaired insulin action (yang2024experimentalcellmodels pages 16-16).

Lipid droplet accumulation is also a critical indicator of metabolic imbalance. In PCOS models, aberrant lipid metabolism leads to the deposition of lipid droplets within cells, particularly in adipocytes and hepatocytes. Staining with lipophilic dyes (such as Nile Red or Oil Red O) followed by high-content imaging or automated quantification offers a sensitive means of assessing lipid accumulation, providing insights into the cellular lipid handling defects that coincide with insulin resistance (yang2024experimentalcellmodels pages 13-14).

Finally, integration of these biochemical endpoints into high-content screening platforms is essential for delineating the molecular underpinnings of PCOS. Candidate endpoints—including GLUT4 translocation, quantitative IRS phosphorylation status, mitochondrial respiration parameters, ROS generation, and lipid droplet quantification—enable simultaneous multiparametric analyses. This holistic approach facilitates the identification of potential therapeutic targets and chemical modulators, thereby advancing the development of drugs that can restore normal insulin signaling and metabolic function in PCOS cells (NCT05146063, NCT05966792).

Collectively, by combining these targeted assays and endpoints, PCOS cell models not only recapitulate key features of insulin resistance but also provide a robust framework for high-content screening of therapeutic candidates aimed at mitigating metabolic dysfunction in PCOS (OpenTargets Search: Polycystic Ovary Syndrome, yang2024experimentalcellmodels pages 4-5).

References:
1. (NCT02302326): Antonio Hernandez Mijares. Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana. 2013. ClinicalTrials.gov Identifier: NCT02302326

2. (NCT02943291):  Adipose Tissue Function and Response to Exercise Training in Women With and Without Polycystic Ovary Syndrome. Norwegian University of Science and Technology. 2016. ClinicalTrials.gov Identifier: NCT02943291

3. (yang2024experimentalcellmodels pages 10-12): Ying Yang, Ting-ting Wang, Hu-ai Xie, Ping Ping Hu, and Pan Li. Experimental cell models of insulin resistance: overview and appraisal. Frontiers in Endocrinology, Dec 2024. URL: https://doi.org/10.3389/fendo.2024.1469565, doi:10.3389/fendo.2024.1469565. This article has 2 citations and is from a peer-reviewed journal.

4. (yang2024experimentalcellmodels pages 13-14): Ying Yang, Ting-ting Wang, Hu-ai Xie, Ping Ping Hu, and Pan Li. Experimental cell models of insulin resistance: overview and appraisal. Frontiers in Endocrinology, Dec 2024. URL: https://doi.org/10.3389/fendo.2024.1469565, doi:10.3389/fendo.2024.1469565. This article has 2 citations and is from a peer-reviewed journal.

5. (yang2024experimentalcellmodels pages 16-16): Ying Yang, Ting-ting Wang, Hu-ai Xie, Ping Ping Hu, and Pan Li. Experimental cell models of insulin resistance: overview and appraisal. Frontiers in Endocrinology, Dec 2024. URL: https://doi.org/10.3389/fendo.2024.1469565, doi:10.3389/fendo.2024.1469565. This article has 2 citations and is from a peer-reviewed journal.

6. (yang2024experimentalcellmodels pages 8-9): Ying Yang, Ting-ting Wang, Hu-ai Xie, Ping Ping Hu, and Pan Li. Experimental cell models of insulin resistance: overview and appraisal. Frontiers in Endocrinology, Dec 2024. URL: https://doi.org/10.3389/fendo.2024.1469565, doi:10.3389/fendo.2024.1469565. This article has 2 citations and is from a peer-reviewed journal.

7. (yang2024experimentalcellmodels pages 9-10): Ying Yang, Ting-ting Wang, Hu-ai Xie, Ping Ping Hu, and Pan Li. Experimental cell models of insulin resistance: overview and appraisal. Frontiers in Endocrinology, Dec 2024. URL: https://doi.org/10.3389/fendo.2024.1469565, doi:10.3389/fendo.2024.1469565. This article has 2 citations and is from a peer-reviewed journal.

8. (NCT05146063):  LNK in Polycystic Ovary Syndrome With Insulin Resistance. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. 2021. ClinicalTrials.gov Identifier: NCT05146063

9. (NCT05966792): Zhang Manna. SGLT2 Inhibitors in Treating Patients With PCOS. Shanghai 10th People's Hospital. 2023. ClinicalTrials.gov Identifier: NCT05966792

10. (OpenTargets Search: Polycystic Ovary Syndrome): Open Targets Query (Polycystic Ovary Syndrome, 25 results). Ochoa, D. et al. (2023). The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Research.

11. (yang2024experimentalcellmodels pages 4-5): Ying Yang, Ting-ting Wang, Hu-ai Xie, Ping Ping Hu, and Pan Li. Experimental cell models of insulin resistance: overview and appraisal. Frontiers in Endocrinology, Dec 2024. URL: https://doi.org/10.3389/fendo.2024.1469565, doi:10.3389/fendo.2024.1469565. This article has 2 citations and is from a peer-reviewed journal.
